

The public reporting burden of this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to—CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333 ATTN: PRA (0920-XXXX)

ORS Annual Evaluation Survey- Public Health Analyst

Thank you for participating in this brief survey about your participation in the Overdose Response Strategy (ORS) program. With this annual survey, we are seeking to understand the components of partnership, networks and mutually reinforcing activities that lead to shared, effective efforts to reduce drug overdoses and save lives. The results will be used to measure the progression and impacts of this unique partnership. We're asking that you respond to the questions based on how the ORS program operated in 2024. The survey will take approximately 30 minutes to complete, and your responses are completely anonymous. The data collected from this survey will be summarized and no individual person will be identifiable from the summarized results. If you have questions or need help with the survey, please contact ORSperformance@cdcfoundation.org. We truly value your experience and feedback!

1. When did your jurisdiction join the ORS program?
 - 2 years or less
 - 3-5 years
 - More than 5 years (before 2020)
2. Have you been in your role with the ORS for 6 or more months? Yes or No

"Backbone" Support from the ORS Program

The ORS was created to help local communities reduce drug overdoses and save lives by sharing timely data, pertinent intelligence and evidence-based and innovative strategies. For the following questions, select the option that best describes to what extent you agree with the statement for the ORS program as it operated in 2024.

3. The ORS program builds a common understanding of the problem that needs to be addressed.
4. The ORS program builds and maintains motivation among key stakeholders to achieve the program's goals.
5. The ORS program provides support toward identified goals and opportunities, and identifies challenges and gaps.
6. The ORS program understands how local context influences implementation of ORS goals.
7. The ORS program is committed to and actively involved in achieving our state/jurisdictional goals.
8. As a result of the involvement with the ORS program, public health and public safety collaboration and communication in my state/jurisdiction is stronger.

9. As a result of the involvement with the ORS program, our state/jurisdictional efforts can better address overdoses.
10. I feel supported in my role by ORS program leadership.

Partner Relationships/Attributes

For the following questions, select the option that best describes to what extent you agree with the statement for your **ORS public health partner**. "**ORS public health partner**" refers to the primary public health agency that you are assigned to.

11. My ORS public health partner has clear approaches/goals for our contribution to the ORS program.
12. My ORS public health partner works collaboratively to identify and implement strategies.
13. My ORS public health partner takes part in activities to build trust and connection across sectors.
14. My ORS public health partner engages in frank, open and respectful discussion specifically about each other's needs and/or priorities as it relates to the ORS.
15. My ORS public health partner is committed to and actively involved in achieving our state/jurisdictional ORS program goals.

For the following questions, select the option that best describes to what extent you agree with the statement for your **ORS public safety partner**. "**ORS public safety partner**" refers to the HIDTA your DIO is assigned to.

16. My ORS public safety partner has clear approaches/goals for our contribution to the ORS program.
17. My ORS public safety partner works collaboratively to identify and implement strategies.
18. My ORS public safety partner takes part in activities to build trust and connection across sectors.
19. My ORS public safety partner engages in frank, open and respectful discussion specifically about each other's needs and/or priorities as it relates to the ORS.
20. My ORS public safety partner is committed to and actively involved in achieving our state/jurisdictional ORS program goals.
21. Indicate the best fit for the current level of involvement with your ORS public health safety from your perspective.
22. Identify your desired level of involvement with this partner.
23. If you are not at your desired level of collaboration, what characteristics would need to change to reach it?

For the following questions, select the option that best describes to what extent you agree with the statement for your **DIO**.

24. My DIO has clear approaches/goals for our contribution to the ORS program.
25. My DIO works collaboratively to identify and implement strategies.
26. My DIO takes part in activities to build trust and connection across sectors.

- 27. My DIO engages in frank, open and respectful discussion specifically about each other's needs and/or priorities as it relates to the ORS.
- 28. My DIO is committed to and actively involved in achieving our state/jurisdictional ORS program goals.
- 29. I work with my DIO to develop and/or disseminate tools to enhance implementation of evidence-based programs and practices.

Local Implementation of the ORS partnership model

For the following questions, select the option that best describes to what extent you agree with the statement for **all** ORS program state/jurisdictional partners as it operated in 2024.

- 30. Together, my public health and public safety partners regularly share data, insights and trends we are seeing related to drug overdose in our communities.
 - a. Agree: please provide specific examples in your jurisdiction from 2024.
 - b. Disagree: Optional: Please elaborate on your selection.
- 31. Together, my public health and public safety partners inform and help local communities develop local solutions to reduce overdoses and save lives.
 - a. Agree: please provide specific examples in your jurisdiction from 2024.
 - b. Disagree: Optional: Please elaborate on your selection.
- 32. Together, my public health and public safety partners implement evidence-based response efforts that can directly reduce overdose deaths.
 - a. Agree: please provide specific examples in your jurisdiction from 2024.
 - b. Disagree: Optional: Please elaborate on your selection.
- 33. Together, my public health and public safety partners design and use promising strategies at the intersection of public health and public safety.
 - a. Agree: please provide specific examples in your jurisdiction from 2024.
 - b. Disagree: Optional: Please elaborate on your selection.
- 34. Together, my public health and public safety partners implement evidence-informed prevention strategies that can reduce substance use and overdose.
 - a. Agree: please provide specific examples in your jurisdiction from 2024.
 - b. Disagree: Optional: Please elaborate on your selection.
- 35. The ORS partners in my state/jurisdiction are doing a good job leveraging the strengths and assets of **public health** to reduce fatal and non-fatal overdoses.
 - a. Agree: please describe specific strengths and assets used.
 - b. Disagree: Optional: Please elaborate on your selection.
- 36. The ORS partners in my state/jurisdiction are doing a good job leveraging the strengths and assets of **public safety** to reduce fatal and non-fatal overdoses.
 - a. Agree: please describe specific strengths and assets used.
 - b. Disagree: Optional: Please elaborate on your selection.
- 37. Since partnering with the ORS program, my public health partner is making improved decisions about policies or programs, and the use of resources to reduce fatal and non-fatal overdoses.
 - a. Agree: please describe specific decisions made about policies and programs or use of resources.
 - b. Disagree: Optional: Please elaborate on your selection.

38. What communities experience greater burden of overdose in your jurisdiction, and how has your ORS partnership worked to reduce these disparities?
39. How has your ORS partnership addressed social, structural, and systemic factors that impact substance use and overdose?

Doing the work

40. The state/jurisdictional ORS Action Plan captures the shared priorities for the ORS team in my jurisdiction.
41. I am directly involved with achieving the goals of the ORS Action Plan.
42. I am clear on my roles and responsibilities to achieve the goals in our ORS Action Plan.
43. I am clear on the roles and responsibilities of my DIO to achieve the goals in our ORS Action Plan.
44. My public health partner provides the necessary support to achieve the goals in our ORS Action Plan.
45. My public safety partner provides the necessary support to achieve the goals in our ORS Action Plan.

Impact of Partnership

46. Looking back at 2024, what do you think was the most significant change in collaboration across public health and public safety in your jurisdiction as a result of your participation in the ORS?
47. What have been the most challenging aspects of this collaboration?
48. What suggestions or ideas do you have for improving collaboration between public health and public safety partners?
49. In what ways have overdose and related trends changed in the last year, if at all, as a result of public health-public safety partnership in your jurisdiction?
50. What about the ORS program has been the most impactful on your public health partner's ability to contribute to the reduction of fatal and non-fatal overdoses?
51. What about the ORS program has been the most impactful on your public safety partner's ability to contribute to the reduction of fatal and non-fatal overdoses?
52. What is your vision for the future of the ORS program?
53. Is there any other feedback you would like to share? (optional)